Repligen Corporation (RGEN) Stock Price & How to Invest

Repligen Corporation makes consumable products and equipment used to manufacture biologic drugs, including monoclonal antibodies, gene therapies and vaccines. Its portfolio spans four franchises: filtration (KrosFlo and XCell ATF systems), chromatography resins and columns, proteins (notably Protein A ligands used to purify antibodies), and process analytics. Because roughly 80% of its offerings face limited direct competition and its consumables are embedded in customers' validated manufacturing processes, Repligen sells into a durable, recurring bioprocessing demand base rather than one-off equipment cycles.

The investment picture is one of recovery from the post-pandemic bioprocessing destocking slump. In Q1 2026 revenue rose 15% as reported and 11% organic, with China sales doubling and analytics surging, prompting management to raise adjusted EPS guidance. Q2 2026 followed with revenue of ~$204 million (up ~12% year over year) and adjusted EPS of $0.54 against a ~$0.45 estimate, Repligen's fourth straight quarterly beat. Trailing-twelve-month revenue is now ~$785 million, while GAAP net income of ~$42 million is far thinner than adjusted figures because of amortization and other charges.

On October 6, 2026 Repligen completed its acquisition of BioLife Solutions, a supplier of cell processing tools and biopreservation media (its CryoStor media supports 18 approved therapies), paying $11.25 in cash plus 0.1442 Repligen shares for each BioLife share, a deal reported at about $1.5 billion when announced. Management said it would quantify the effect on its 2026 outlook on the Q3 call on October 27, 2026; consensus for that quarter sits near $0.46 of EPS on ~$207 million of revenue, and analysts model ~$1.08 billion of revenue for 2027 as BioLife is folded in. The shares closed at $175.35 on October 16, 2026, up ~7% year to date and ~13.5% over one year (and ~28% over three months), for a market cap of ~$11.1 billion. The debate for investors still centers on valuation: at roughly 14 times trailing sales and ~66 times forward earnings, the shares price in a sustained return to double-digit growth.

Repligen trades at a rich valuation (around 14 times trailing sales and ~66 times forward earnings in October 2026), so any stumble in organic growth or guidance can trigger sharp multiple compression. The business is cyclical and sensitive to biopharma capital spending, funding conditions for smaller biotech customers, and inventory destocking, all of which hurt results in 2023 to 2024. Concentration among large pharma and CDMO customers, exposure to China and global tariff or trade policy, and integration risk from acquisitions add uncertainty, now sharpened by the BioLife deal: cell therapy is a smaller, more volatile end market than antibodies, the stock portion of the consideration added to Repligen's share count, and the deal's effect on 2026 guidance was still undisclosed as of mid-October. Competition from far larger rivals like Danaher's Cytiva and Sartorius could pressure pricing in overlapping product lines. Finally, as an equipment and consumables supplier, revenue can be lumpy quarter to quarter.

20 analysts publish price targets on RGEN, averaging $197.95 against a $175.42 price as of October 2026, or +12.8%. The published targets run from $145.00 to $235.00, a moderate spread, and the ratings split 18 buy, 4 hold, 0 sell. Over the last six months there have been 6 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RGEN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Repligen Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Bioprocessing recovery and organic reacceleration. After a multi-year destocking correction, Repligen returned to double-digit organic growth in early 2026 (11% organic in Q1, then ~12% reported growth in Q2) with broad-based strength across franchises and geographies. The most optimistic published target, $235.00, assumes this works close to its best case.

The case against. Repligen trades at a rich valuation (around 14 times trailing sales and ~66 times forward earnings in October 2026), so any stumble in organic growth or guidance can trigger sharp multiple compression. The most pessimistic target, $145.00, is roughly what RGEN is worth if this bites instead.

Read the full bull and bear case on RGEN, including what would have to change to break either one. Walnut is not an investment adviser.

No. Repligen Corporation (RGEN) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Repligen Corporation's investor relations page or your broker.

• Revenue (TTM): ~$785M
• Q2 2026 revenue growth: ~12% YoY (~$204M)
• Q2 2026 adjusted EPS: ~$0.54 (vs ~$0.45 est.)
• Net income (TTM, GAAP): ~$42M (~5% margin)
• P/E (trailing / forward): ~240x / ~66x
• Price/sales: ~14x
• Market cap: ~$11.1B

As of October 16, 2026, Repligen trades near 14 times trailing sales and ~66 times forward earnings, a premium even among life-science tools names; the ~240x trailing GAAP P/E reflects thin reported profit rather than the adjusted figures management guides to. The shares have climbed ~28% over three months on steady earnings beats, and the next leg of the debate turns on how much the BioLife deal adds to 2027 revenue (consensus ~$1.08 billion) and at what margin.

If you want RGEN exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to RGEN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get RGEN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FBT), which spreads the position across many companies. Or build it into a focused thematic portfolio, so RGEN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RGEN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Repligen is a high-quality, high-multiple bioprocessing supplier whose story hinges on whether reaccelerating organic growth, plus the newly closed BioLife Solutions deal, can justify a valuation of roughly 14 times trailing sales; third-quarter results on October 27, 2026 are the first chance to see management's updated outlook.

Whether RGEN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RGEN a buy or a sell?, and where the stock could go from here in the RGEN stock forecast.

For income investors, whether RGEN pays a dividend and how the payout looks is covered in does RGEN pay a dividend? And to weigh RGEN against a peer, read the full side-by-side comparisons: RGEN vs DHR and RGEN vs TMO.